Blueprint Medicines is committed to leveraging the power of our drug discovery platform to deliver transformative, targeted medicines to a broad spectrum of patients with genomically defined diseases driven by the abnormal activation of kinases.

Our platform spans a wide range of disease areas. While we may expand into other disease areas in the future, our current focus is on genomically defined cancers, which enables a cost-efficient discovery and development strategy. We own worldwide commercialization rights to our lead drug candidates, avapritinib and BLU-554, as well as to our other drug candidates in discovery and development including BLU-667.

In March 2016, we announced a worldwide collaboration with Roche to accelerate and expand the discovery, development, and commercialization of up to five small molecule therapeutics targeting kinases believed to be important in cancer immunotherapy.

We will continue to evaluate collaborations to maximize the value of our programs, allowing us to expand our geographic reach or leverage the expertise of strategic partners.

For partnering inquiries, please contact